Delivery Order SPE2DB22D3016-SPE2DB25FBJN4
Award Date 9/16/25
Potential Completion Date 10/7/25
Potential Value $54K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $48,077.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Ocrevus 300 mg/10 ml vials on September 26, 2025, with an ultimate completion date of October 20, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ocrevus is a disease-modifying therapy used to treat multiple sclerosis, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $48,077.16 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials. This non-set-aside, firm fixed price delivery order is scheduled for completion by September 3, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. Ocrevus is a specialty pharmaceutical product used in the treatment of multiple sclerosis, reflecting the critical role AmerisourceBergen plays in supplying...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials, with a ceiling value of $24,038.58 and a firm fixed price structure. This delivery order is a non-set-aside competitive award with a completion deadline of December 1, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Ocrevus is a monoclonal antibody used primarily to treat...
- The Defense Logistics Agency awarded a $48,077.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on September 19, 2025, with an ultimate completion date of October 10, 2025. This non-competitive delivery order was placed against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on August 25, 2025, with a contract ceiling value of $24,038.58 and an ultimate completion date of September 16, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under DLA's procurement processes. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of OCREVUS 300 mg/10 mL vials valued at $36,057.84 under a Firm Fixed Price contract type. This delivery order, which is not set-aside and was competitively awarded, is scheduled for completion by September 11, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract represents a child order under...
- The Defense Logistics Agency awarded a $136,567.97 delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials on April 24, 2025, with completion expected by May 15, 2025. This firm fixed-price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be...
- The Defense Logistics Agency (DLA) awarded a $29,496.97 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This non-set-aside competitive award is scheduled for completion by August 18, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. Ocrevus is a specialty pharmaceutical used primarily for treating multiple sclerosis, reflecting the federal government's ongoing...
- The Defense Logistics Agency awarded a delivery order valued at $52,433.04 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and requires completion by December 2, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Ocrevus is a specialty pharmaceutical product used in the...
- The Defense Logistics Agency awarded a $120,192.80 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed-price contract with an ultimate completion date of August 14, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting the contractor's demonstrated capability to meet federal pharmaceutical...